Inovio Pharmaceuticals (INO) Operating Leases (2019 - 2026)

Inovio Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $8.0 million for Q2 2026.

• In Q2 2026, Operating Leases fell 24.92% year-over-year to $8.0 million; the TTM figure through Jun 2026 stood at $8.0 million (down 24.92% YoY), while the FY2025 annual figure was $6.5 million, down 30.13% from the prior year.
• Operating Leases came in at $8.0 million for Q2 2026 at Inovio Pharmaceuticals, down from $8.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $17.4 million in Q1 2022 to a low of $6.5 million in Q4 2025.
• Average Operating Leases over 5 years is $12.2 million, with a median of $12.6 million recorded in 2022.
• Year-over-year, Operating Leases declined 6.51% in 2024 and sank 30.13% in 2025.
• Over 5 years, Operating Leases stood at $12.7 million in 2022, then fell by 12.83% to $11.0 million in 2023, then fell by 15.09% to $9.4 million in 2024, then slumped by 30.13% to $6.5 million in 2025, then rose by 22.26% to $8.0 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $8.0 million in Q2 2026, $8.7 million in Q1 2026, and $6.5 million in Q4 2025.